August 1, 2024 08:56 AM EDT
Deals
Pharma

Ab­b­Vie clos­es $8.7B Cerev­el deal in bid to com­pete with Bris­tol My­ers in schiz­o­phre­nia

Kyle LaHucik

Senior Reporter

Ab­b­Vie has re­ceived reg­u­la­to­ry clear­ance to com­plete its $8.7 bil­lion ac­qui­si­tion of neu­ro­science biotech Cerev­el Ther­a­peu­tics, the com­pa­nies

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times